Return to site

Blood Screening Market Dynamics 2021

Market Dynamics Driving
  • Increasing Number of Blood Donations and Blood Donors
  • Increasing Demand of Donated Blood
  • Rising Prevalence of Infectious Diseases
  • Growing Affordability and Adoption of NAT for Blood Screening
  • Rising Awareness Regarding the Safety of Donated Blood
Restraints
  • Capital Expenditure and Operating Costs of NAT
  • Lack of Regulations Mandating the Use of NAT in Developing Countries
  • Emergence of Alternative Technologies
Opportunities
  • Pathogen Reduction Technology
  • Multiplex Tests
  • Emerging Economies
The global blood screening market is expected to reach USD 2.80 billion by 2021 from USD 1.76 billion in 2016, at a CAGR of 9.7%.
The global blood screening market is broadly classified into technology, product & service, end user, and region. The ELISA segment is projected to register the highest CAGR during the forecast period. The increasing number of donations, its low cost, growing prevalence/incidence of infectious diseases, and the increasing demand for donated blood are the major factors contributing to the growth of the ELISA market.

Moreover, the high cost of NAT testing makes it unaffordable for developing economies, leaving them to rely on ELISA testing for blood screening.